Janus Henderson Group PLC Prothena Corp Public LTD CO Transaction History

Janus Henderson Group PLC

$187 Billion
Q3 2024

A detailed history of Janus Henderson Group PLC transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Janus Henderson Group PLC holds 18,047 shares of PRTA stock, worth $259,876. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,047

Previous 1,026,558 98.24%

Holding current value

$259,876

Previous $21.2 Million 98.58%

% of portfolio

0.0%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$16.73 - $24.79 $16.9 Million - $25 Million	-1,008,511 Reduced 98.24%	18,047 $301,000
Q2 2024 Aug 14, 2024	SELL	$19.54 - $26.15 $5.53 Million - $7.4 Million	-283,032 Reduced 21.61%	1,026,558 $21.2 Million
Q1 2024 May 15, 2024	SELL	$24.75 - $40.66 $18 Million - $29.5 Million	-726,394 Reduced 35.68%	1,309,590 $32.4 Million
Q4 2023 Feb 14, 2024	BUY	$32.31 - $52.32 $6.76 Million - $11 Million	209,375 Added 11.46%	2,035,984 $74 Million
Q3 2023 Nov 14, 2023	BUY	$47.3 - $70.6 $7.29 Million - $10.9 Million	154,078 Added 9.21%	1,826,609 $88.1 Million
Q2 2023 Aug 14, 2023	BUY	$48.26 - $78.59 $3.68 Million - $5.99 Million	76,228 Added 4.78%	1,672,531 $114 Million
Q1 2023 May 15, 2023	BUY	$46.97 - $58.27 $7.7 Million - $9.56 Million	163,980 Added 11.45%	1,596,303 $77.4 Million
Q4 2022 Feb 14, 2023	BUY	$52.05 - $65.0 $66.6 Million - $83.2 Million	1,279,375 Added 836.48%	1,432,323 $86.3 Million
Q3 2022 Nov 14, 2022	SELL	$25.16 - $60.63 $757,114 - $1.82 Million	-30,092 Reduced 16.44%	152,948 $9.28 Million
Q2 2022 Aug 15, 2022	BUY	$22.73 - $39.98 $4.04 Million - $7.1 Million	177,545 Added 3231.03%	183,040 $4.97 Million
Q4 2021 Feb 14, 2022	BUY	$42.11 - $73.26 $231,394 - $402,563	5,495 New	5,495 $272,000

Others Institutions Holding PRTA

# of Institutions

184

Shares Held

42.7M

Call Options Held

162K

Put Options Held

102K

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $676M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account

Janus Henderson Group PLC Prothena Corp Public LTD CO Transaction History